Jeevan Scientific Technology
- Market cap
- ₹ 163 Cr.
- P/E
- 46.9x
- P/B
- 2.31x
- 52-week range
- 57.15 – 93.9
- ROE
- 2%
- ROCE
- 5%
- Dividend yield
- 0%
- Debt / equity
- 0.3
- Sector
- Healthcare Services
- Industry
- Healthcare Research, Analytics & Technology
- Listed on
- BSE
About
Jeevan Scientific Technology Limited provides technology-driven services and solutions to its clients across the globe. The Company’s service portfolio enables its clients to provide an integrated solution for the management of clinical data from its inception to completion. It offers a range of clinical trial services from Phase II to IV for pharmaceutical, biotechnology and medical devices to bring new drugs and devices. It also provides its services to other areas, such as cosmetics and nutraceuticals. Its clinical trial services include medical writing, clinical trial management, clinical trial monitoring, drug safety management, clinical data management, biostatistics and statistical programming, and quality assurance. It offers comprehensive pharmacovigilance and safety monitoring services from early development support through post-approval initiatives. BA/BE Studies offers clinical services, bioanalytical services, pharmacokinetic & bio-statistics, and glucose clamping.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Research, Analytics & Technology: 11 companies →Jeevan Scientific Technology against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)46.9 against a typical 34.2: pricier than most peers (1st = cheapest).8th of 11
- Sales growth+107.7% against a typical +16.4% from a year earlier.1st of 10
- Share price, 3 months+13.5% against a typical −13%.3rd of 11
- Size₹ 163.1 Cr. market value against a typical ₹ 197.8 Cr. (1st = largest).8th of 11
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8 | 10 | 11 | 13 | 11 | 13 | 10 | 9 | 12 | 19 | 21 | 18 |
| Expenses | 7 | 9 | 10 | 10 | 9 | 10 | 10 | 11 | 10 | 14 | 17 | 15 |
| Operating Profit | 1 | 1 | 1 | 3 | 3 | 2 | −0 | −2 | 2 | 5 | 4 | 3 |
| OPM % | 7.4% | 10% | 8.9% | 25.1% | 21.9% | 16.6% | −3.8% | −20.2% | 16.7% | 27.4% | 20.2% | 16.1% |
| Other Income | 0 | −0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| Depreciation | 1 | 1 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | −1 | −1 | −1 | 2 | 1 | 0 | −3 | −4 | 0 | 3 | 3 | 1 |
| Tax % | −25.3% | −24.6% | −4% | 31.3% | 65.3% | 89.7% | −50.6% | −13.7% | 66.7% | 25.7% | 28.5% | 11.2% |
| Net Profit | −1 | −0 | −1 | 1 | 0 | 0 | −1 | −3 | 0 | 2 | 2 | 1 |
| EPS in Rs | −0.39 | −0.31 | −0.47 | 0.7 | 0.16 | 0.07 | −0.82 | −1.96 | −0.06 | 0.9 | 0.81 | 0.27 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 13%
- 5 Years
- 6%
- 3 Years
- 19%
- TTM
- 66%
- 10 Years
- 45%
- 5 Years
- −37%
- 3 Years
- 33%
- TTM
- 186%
- 10 Years
- 11%
- 5 Years
- −4%
- 3 Years
- 3%
- TTM
- —
- 10 Years
- 3%
- 5 Years
- 2%
- 3 Years
- 0%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Jeevan Scientific Technology | ₹ 81.90 | ₹ 163 Cr. | 46.9x | 2.3x | 2% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Srinivas Reddy Maram
- Chief Executive Officer
- Krishna Kishore Kuchipudi
- Vice Chairman of the Board, Managing Director
- Venkateswara Rao Rao Ravipati
- Chief Financial Officer
- Krishna Sainadh Kodati
- Compliance Officer, Company Secretary
- Snigdha Mothukuri
- Executive Director
- Y. Nageswar Rao
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.